Regulus Therapeutics reported $52.13M in Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Alnylam Pharmaceuticals ALNY:US USD 3.55B 11.1M
AstraZeneca AZN:LN USD 96.48B 2.3B
Astrazeneca AZN:US USD 96.48B 2.3B
Biogen BIIB:US USD 24.55B 300.1M
Celldex Therapeutics CLDX:US USD 352.73M 16.49M
Gilead Sciences GILD:US USD 63.17B 614M
GlaxoSmithKline GSK:LN GBP 60.15B 167M
Intercept Pharmaceuticals ICPT:US USD 553.71M 5.69M
Intrexon XON:US USD 215.98M 43.27M
Lexicon Pharmaceuticals LXRX:US USD 194.3M 2.61M
Ligand Pharmaceuticals LGND:US USD 762.67M 287.94M
Omeros OMER:US USD 590.97M 133.42M
Regulus Therapeutics RGLS:US USD 52.13M 2.17M
Sangamo Biosciences SGMO:US USD 562.51M 31.4M
Spectrum Pharmaceuticals SPPI:US USD 118.93M 39.5M
Takeda 4502:JP JPY 13.5T 1.08T
Vital Therapies VTL:US USD 127.75M 6.67M
YTE INCY:US USD 5.84B 330.77M